Dejun Tang

Dr. Dejun Tang

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
JDJohn P. DiMarco
John P. DiMarco
POPaul O’cOnnor
Paul O’cOnnor
JCJeffrey A. Cohen
Jeffrey A. Cohen
ARAnthony t Reder
Anthony t Reder
LZLixin Zhang-Auberson
Lixin Zhang-Auberson
LKLudwig Kappos
Ludwig Kappos

1 August 2019 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
PDF file
HUHajime Uno
Hajime Uno
DSDeborah Schrag
Deborah Schrag
DKDae Hyun Kim
Dae Hyun Kim
DTDejun Tang
Dejun Tang
LTLu Tian
Lu Tian
LWLee-Jen Wei
Lee-Jen Wei
A typical biosimilar study in oncology uses the overall response evaluated at a specific time point as the primary endpoint, which is generally acceptable regulatorily, to assess clinical equivalence between a biosimilar and its reference product. The standard primary endpoint for evaluating an anticancer therapy, progression-free or overall survival would be a secondary endpoint in a biosimilar trial. With a conventional analytic procedure via, for example, hazard ratio to quantify the group difference, it is difficult and challenging to assess clinical equivalence with respect to progression-free or overall survival because the study generally has a limited number of clinical events observed in the study. In this article, we show that an alternative procedure based on the restricted mean survival time, which has been discussed extensively for design and analysis of a general equivalence study, is readily applicable to a biosimilar trial. Unlike the hazard ratio, this procedure provides a clinically interpretable estimate for assessing equivalence. Using the restricted mean survival time as a summary measure of the survival curve will enhance better treatment decision making in adopting a biosimilar product over the reference product.

2 January 2019 in Statistics in Biopharmaceutical Research
Verified
Journal Article
Closed access
DTDejun Tang
Dejun Tang
PGPaul Gallo
Paul Gallo
We discuss concepts, regulatory pathways, and some statistical methodological issues related to the concept of interchangeability in biosimilar development. Starting with key aspects reflected in health authority guidance documents, we summarize the definition and requirements in both the United States and European Union for interchangeability. The design of clinical studies for interchangeability will then be discussed. Furthermore, three scenarios of adaptive designs will be presented and summarized.

12 February 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
LCLiyi Cen
Liyi Cen
RARamin Arani
Ramin Arani
DTDejun Tang
Dejun Tang
Background/Objectives: Biosimilar studies use overall response rate to assess clinical similarity. Sample size and power depend on the equivalence margin, defined in either risk difference or risk ratio scale. This manuscript investigates how different evaluation metrics and varying response rates affect study power. Methods: Two numerical simulations are conducted. The first is designed to test in the risk difference scale, while the second tests in the risk ratio scale. Both simulations consider no difference between the biosimilar and reference product. Response rates vary from 0.1 to 0.9, and all scenarios are repeated 10,000 times. Results: The study shows inconsistent results in testing the equivalence of overall response rate across the risk difference and risk ratio scales, even when the hypotheses are mathematically equivalent. Consequently, the study is often under powered for testing in both scales. Additionally, study power is sensitive to outcome response rate deviation, with different directions of change in the two different evaluation metrics. Conclusions: Biosimilar study design should avoid the concept of converting equivalence margins between risk difference and risk ratio scales, assuming no change in study power. Careful strategies should be planned for estimating overall response rates for sample size assessments.